All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Protein melan-A also known as melanoma antigen recognized by T cells 1 or MART-1 is a protein that in humans is encoded by the MLANA gene. A fragment of the protein, usually consisting of the nine amino acids 27 to 35, is bound by MHC class I complexes which present it to T cells of the immune system. These complexes can be found on the surface of melanoma cells. Decameric peptides (26-35) are being investigated as cancer vaccines.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L072 | Human anti-MLANA (ELAGIGILTV) T Cell Receptor, pLXSN | Human | Human | ELAGIGILTV | HLA-A2 | retroviral vector | ||
TCR-L071Z | Human anti-melan-A T cell receptor, pCDTCR1 | Human | Human | ELAGIGILTV | HLA-A2 | Lentiviral | ||
TCR-L251 | Human anti-melan-A T cell receptor (SW-M1-9), pCDTCR1 | Human | SW-M1-9 | Human | ELAGIGILTV: | HLA-A*0201 | Lentiviral | |
TCR-L252 | Human anti-melan-A T cell receptor (SW-M1-29), pCDTCR1 | Human | SW-M1-29 | Human | ELAGIGILTV: | HLA-A*0201 | Lentiviral | |
TCR-L253 | Human anti-melan-A T cell receptor (SW-M1-54), pCDTCR1 | Human | SW-M1-54 | Human | ELAGIGILTV: | HLA-A*0201 | Lentiviral | |
TCR-L254 | Human anti-melan-A T cell receptor (SW-M1-66), pCDTCR1 | Human | SW-M1-66 | Human | ELAGIGILTV: | HLA-A*0201 | Lentiviral | |
TCR-L255 | Human anti-melan-A T cell receptor (SW-M1-67), pCDTCR1 | Human | SW-M1-67 | Human | ELAGIGILTV: | HLA-A*0201 | Lentiviral | |
XS-0623-LX14 | Anti-Melan-A (PD1/28-F4 TCR) T cell receptor, pCDTCR1 Vector | Human | F4 | Human | AA26–35 | HLA-A2 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION